Clinical Trials Logo

Non-hodgkin Lymphoma,B Cell clinical trials

View clinical trials related to Non-hodgkin Lymphoma,B Cell.

Filter by:

NCT ID: NCT04435743 Recruiting - Clinical trials for Non-hodgkin Lymphoma,B Cell

Efficacy and Safety of Lenalidomide With or Without Rituximab and Other Drugs in B-cell Non-Hodgkin's Lymphomas

Start date: November 1, 2019
Phase:
Study type: Observational

Describe the treatment of B-cell non-Hodgkin lymphoma patients who receive lenalidomide single drug or lenalidomide combined with rituximab (with or without other drugs), and evaluate the efficacy and safety of lenalidomide single drug or lenalidomide combined with rituximab (with or without other drugs) in the real-world setting.

NCT ID: NCT03720496 Recruiting - Clinical trials for Non-hodgkin Lymphoma,B Cell

Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With CD19-TriCART Cell Therapy

Start date: November 1, 2018
Phase: Phase 1
Study type: Interventional

This is a single arm, open-label, phase Ⅰ study, to determine the safety and efficacy of CD19-TriCAR-T, an autologous tri-functional anti- CD19 chimeric antigen receptor (CAR)-positive T cell therapy, in Refractory/ Relapsed CD19 Positive Non-Hodgkin Lymphoma (NHL).

NCT ID: NCT03497533 Recruiting - Clinical trials for Non-hodgkin Lymphoma,B Cell

Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With TriCAR-T_CD19

Trident19-H
Start date: August 3, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This is a single arm, open-label, single-center, phase 1/2 study, to determine the safety and efficacy of TriCAR-T-CD19, an autologous tri-functional anti-CD19 chimeric antigen receptor (CAR)-positive T cell therapy, in refractory/Relapsed Non-Hodgkin Lymphoma (NHL).

NCT ID: NCT02772198 Recruiting - Clinical trials for Non-Hodgkin Lymphoma, B-cell

T-cells Expressing Anti-CD19 CAR in Pediatric and Young Adults With B-cell Malignancies

Start date: November 2016
Phase: Phase 1/Phase 2
Study type: Interventional

This phase 1 / 2 study will evaluate the response of B-cell malignancies expressing CD19 to autologous T cells transduced with a second generation anti-CD19 chimeric antigen receptor in children and young adults.

NCT ID: NCT02081937 Recruiting - Clinical trials for Mantle Cell Lymphoma

CART-19 Immunotherapy in Mantle Cell Lymphoma

Start date: March 2014
Phase: Phase 1/Phase 2
Study type: Interventional

Patients receive anti-CD19-CAR (coupled with CD137 and CD3 zeta signalling domains)vector-transduced autologous T cells over a period of 4 or 5 consecutive days in an escalating dose. After completion of study treatment, patients are followed intensively for 6 months, every 3 months for 2 years, and annually thereafter for 10 years.